A Phase 2b, Multicenter, Double-masked, Randomized Study Evaluating the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Subjects With Visual Acuity Impairment Associated With Geographic Atrophy Secondary to Age Related Macular Degeneration

Trial Profile

A Phase 2b, Multicenter, Double-masked, Randomized Study Evaluating the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Subjects With Visual Acuity Impairment Associated With Geographic Atrophy Secondary to Age Related Macular Degeneration

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2018

At a glance

  • Drugs Palucorcel (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PRELUDE
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 15 Jan 2018 Planned End Date changed from 30 Nov 2022 to 31 May 2019.
    • 15 Jan 2018 Status changed from recruiting to active, no longer recruiting.
    • 21 Jan 2017 Planned End Date changed from 1 Mar 2022 to 1 Nov 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top